Cogent Biosciences, Inc.
bezuclastinib
GIST who have received prior treatment with imatinib
Resolved
7days ago
Approval decision · Jun 30, 2026
What's at stake
A final FDA approval decision on bezuclastinib for GIST who have received prior treatment with imatinib is expected Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Pending FDA approval, launch bezuclastinib in the second half of 2026”